Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) EVP John Charles Thomas sold 642 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $302.03, for a total value of $193,903.26. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Krystal Biotech Trading Up 1.3%
NASDAQ:KRYS opened at $306.63 on Thursday. The firm has a market capitalization of $9.04 billion, a PE ratio of 40.99 and a beta of 0.50. The stock has a 50 day moving average of $275.34 and a 200-day moving average of $259.63. Krystal Biotech, Inc. has a 52 week low of $123.03 and a 52 week high of $319.48.
Krystal Biotech (NASDAQ:KRYS – Get Free Report) last issued its quarterly earnings data on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.38. The business had revenue of $116.36 million during the quarter, compared to the consensus estimate of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. As a group, analysts predict that Krystal Biotech, Inc. will post 7.83 EPS for the current fiscal year.
Institutional Investors Weigh In On Krystal Biotech
Analysts Set New Price Targets
KRYS has been the subject of a number of research analyst reports. Weiss Ratings upgraded Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, April 9th. Wall Street Zen upgraded Krystal Biotech from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. The Goldman Sachs Group upped their target price on Krystal Biotech from $206.00 to $327.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Wolfe Research initiated coverage on Krystal Biotech in a research report on Friday, March 27th. They issued a “peer perform” rating for the company. Finally, HC Wainwright restated a “buy” rating and issued a $310.00 target price on shares of Krystal Biotech in a research report on Monday, May 18th. Ten analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $324.11.
View Our Latest Report on KRYS
Krystal Biotech Company Profile
Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.
The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.
Read More
- Five stocks we like better than Krystal Biotech
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
- Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
- Keysight: The AI and Defense Stock Seeing Big Price Target Boosts
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
